- Reuters•11 months ago
Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease. The treatments are awaiting U.S. approval decisions after receiving breakthrough therapy designations from the Food and Drug Administration. "This is sort of a momentous year for us," Alexion Chief Executive David Hallal said in an interview.
- GuruFocus.com•11 months ago
Chicago-based Columbia Wanger (Trades, Portfolio) serves mostly investment companies, managing mutual funds for its clients.
|Bid||N/A x N/A|
|Ask||N/A x N/A|
|52wk Range||undefined - undefined|
|Day's Range||N/A - N/A|
|Avg Vol (3m)||N/A|